Last kr28.90 SEK
Change Today +0.40 / 1.40%
Volume 71.5K
ACTI On Other Exchanges
Symbol
Exchange
Stuttgart
Stockholm
OTC US
OTC US
As of 11:29 AM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

active biotech ab (ACTI) Snapshot

Open
kr28.60
Previous Close
kr28.50
Day High
kr29.50
Day Low
kr28.60
52 Week High
12/3/13 - kr81.50
52 Week Low
03/28/14 - kr27.50
Market Cap
2.2B
Average Volume 10 Days
112.7K
EPS TTM
kr-2.28
Shares Outstanding
74.9M
EX-Date
02/15/01
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACTIVE BIOTECH AB (ACTI)

Related News

No related news articles were found.

active biotech ab (ACTI) Related Businessweek News

No Related Businessweek News Found

active biotech ab (ACTI) Details

Active Biotech AB (publ), a biotechnology company, focuses on developing pharmaceuticals for the treatment of autoimmune/inflammatory diseases and cancer in Sweden. Its projects include Laquinimod, an orally administered compound in Phase III clinical trial development for the treatment of autoimmune diseases, primarily multiple sclerosis; Tasquinimod, which is in Phase III clinical trial for the treatment of prostate cancer; and ANYARA, a protein drug in Phase II/III study for the treatment of renal cell cancer. The company is also developing Paquinimod (57-57), a compound primarily for the treatment of systemic sclerosis; and RhuDex, a compound that is primarily intended to be used as a drug for the treatment of rheumatoid arthritis. Its preclinical project product is ISI (inhibition of S100 interactions) for producing patentable chemical compounds that interact with S100A9, a target molecule for the quinoline compounds. Active Biotech AB (publ) is headquartered in Lund, Sweden.

58 Employees
Last Reported Date: 08/7/14

active biotech ab (ACTI) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr5.0M
Compensation as of Fiscal Year 2013.

active biotech ab (ACTI) Key Developments

Teva Pharmaceutical Industries Ltd. and Active Biotech to Present New Follow-Up Data Evaluating the Clinical Safety of Laquinimod in Patients with Relapsing-Remitting Multiple Sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech announced new follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting multiple sclerosis (RRMS) who were treated with laquinimod in Phase II, Phase III and open-label extension studies for two or more years. The pooled safety analysis of the Phase II LAQ/5063 and the Phase III ALLEGRO and BRAVO extension studies supports findings observed in the core studies where currently identified risks were observed within the first months of laquinimod treatment. These data will be presented as part of a platform presentation, September 12, 2014, at the MS Boston 2014: Joint ACTRIMS-ECTRIMS Meeting being held in Boston, Massachusetts. In the pooled safety analysis, rates of adverse events (AEs) and serious AEs were lower in the open-label extensions than in the core studies and less than 3% of patients discontinued treatment due to AEs during these extensions. Additionally, shifts to potentially significant laboratory values were considerably lower in patients exposed to at least two years of laquinimod (1.18% reached >3xULN ALT vs. 4.72% for laquinimod and 2.6% for placebo during the core study). The safety analysis included patients exposed to laquinimod 0.6 mg for two or more years (n=1009), with a mean exposure of 3.7 (±1.0) years, in the double-blind phase and open-label extensions of the Phase II LAQ/5063 and the Phase III ALLEGRO and BRAVO trials.

Active Biotech AB Reports Unaudited Consolidated and Company Earnings Results for Second Quarter and Six Months Ended June 30, 2014

Active Biotech AB reported unaudited consolidated and company earnings results for second quarter and six months ended June 30, 2014. For the quarter, on consolidated basis, the company’s net sales were SEK 2.7 million against SEK 2.5 million a year ago. Operating loss was SEK 57.9 million against SEK 79.5 million a year ago. Loss before tax was SEK 58.2 million against SEK 81.7 million a year ago. Net loss for the period was SEK 57.7 million against SEK 81.2 million a year ago. Comprehensive loss per share before and after dilution was SEK 0.77 against SEK 1.08 a year ago. For the six months, on consolidated basis, the company’s net sales were SEK 4.9 million against SEK 5.0 million a year ago. Operating loss was SEK 117.2 million against SEK 156.5 million a year ago. Loss before tax was SEK 119.0 million against SEK 160.3 million a year ago. Net loss for the period was SEK 117.9 million against SEK 159.2 million a year ago. Comprehensive loss per share before and after dilution was SEK 1.57 against SEK 2.18 a year ago. Cash used in operating activities was SEK 149.7 million against SEK 93.1 million a year ago. Investments in tangible fixed assets was SEK 0.1 million against SEK 0.1 million a year ago. For the quarter, the company’s net sales were SEK 4.6 million against SEK 4.5 million a year ago. Operating loss was SEK 63.8 million against SEK 85.5 million a year ago. Net loss for the period was SEK 62.4 million against SEK 83.9 million a year ago. For the six months, the company’s net sales were SEK 9.6 million against SEK 9.9 million a year ago. Operating loss was SEK 128.3 million against SEK 167.5 million a year ago. Net loss for the period was SEK 126.3 million against SEK 165.9 million a year ago.

Active Biotech AB Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-10-2014 02:05 PM

Active Biotech AB Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-10-2014 02:05 PM. Venue: New York Palace Hotel – 455 Madison Avenue, New York, NY 10022, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACTI:SS kr28.90 SEK +0.40

ACTI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACTI.
View Industry Companies
 

Industry Analysis

ACTI

Industry Average

Valuation ACTI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.4x
Price/Book 6.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTIVE BIOTECH AB, please visit www.activebiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.